CoChat

Simvastatin as a Treatment for Pulmonary Hypertension Trial

Open access
Wilkins, M. R., Ali, O., Bradlow, W., Wharton, J., Taegtmeyer, A., Rhodes, C. J., Ghofrani, H. A., Howard, L., Nihoyannopoulos, P., Mohiaddin, R. H., Gibbs, J. S. R., for the Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group · 2010 · American Journal of Respiratory and Critical Care Medicine
Cited by 135

The DOI matches its Crossref record.

Abstract

RATIONALE: In animal models of pulmonary hypertension, simvastatin has been shown to reduce pulmonary artery pressure and induce regression of associated right ventricular (RV) hypertrophy. OBJECTIVES: To assess the therapeutic value of simvastatin in patients with pulmonary arterial hypertension (PAH). METHODS: Forty-two patients with PAH were randomized to receive either simvastatin (80 mg/d) or placebo in addition to current care for 6 months, and thereafter offered open-label simvastatin. The primary outcome was change in RV mass, assessed by cardiac magnetic resonance (CMR). MEASUREMENTS AND MAIN RESULTS: At 6 months, RV mass decreased by 5.2 +/- 11 g in the statin group (P = 0.045) and increased 3.9 +/- 14 g in the placebo group. The treatment effect was -9.1 g (P = 0.028). N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels decreased significantly in the statin group (-75 +/- 167 fmol/ml; P = 0.02) but not the placebo group (49 +/- 224 fmol/ml; P = 0.43; overall treatment effect -124 fmol/ml; P = 0.041). There were no significant changes in other outcome measures (including 6-minute walk test, cardiac index, and circulating cytokines). From 6 to 12 months, both RV mass and NT-proBNP increased toward baseline values in 16 patients on active treatment who continued with simvastatin but remained stable in 18 patients who switched from placebo to simvastatin. Two patients required a reduction in dose but not cessation of simvastatin. CONCLUSIONS: Simvastatin added to conventional therapy produces a small and transient early reduction in RV mass and NT-proBNP levels in patients with PAH, but this is not sustained over 12 months.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.2009111-699oc

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 135

Metadata

Authors
Wilkins, M. R., Ali, O., Bradlow, W., Wharton, J., Taegtmeyer, A., Rhodes, C. J., Ghofrani, H. A., Howard, L., Nihoyannopoulos, P., Mohiaddin, R. H., Gibbs, J. S. R., & for the Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2010-05-11
Volume
181
Issue
10
Pages
1106-1113
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1984608205
Cited by
135
References
0
FWCI
13.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simvastatin as a Treatment for Pulmonary Hypertension Trial. https://app.cochat.ai/papers/10.1164/rccm.2009111-699oc
The paper
Wilkins, M. R., Ali, O., Bradlow, W., Wharton, J., Taegtmeyer, A., Rhodes, C. J., Ghofrani, H. A., Howard, L., Nihoyannopoulos, P., Mohiaddin, R. H., Gibbs, J. S. R., & for the Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group. (2010). Simvastatin as a Treatment for Pulmonary Hypertension Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.2009111-699oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.